News

Regeneron’s Lynozyfic Gains Accelerated FDA Approval for Multiple Myeloma
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the most undervalued large cap stocks to buy according to analysts. On ...
GlobalData on MSN5d
Regeneron nabs dosing edge with Lynozyfic’s FDA approval in multiple myeloma
Regeneron has won US Food and Drug Administration (FDA) approval for Lynozyfic (linvoseltamab-gcpt), marking the entry of ...
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year ...
Engineered protein silences harmful T cells in autoimmune disease
An engineered protein turns off the kind of immune cells most likely to damage tissue as part of Type-1 diabetes, hepatitis, ...
23andMe’s ex-CEO is trying to buy the company. A St. Louis judge could decide Friday.
San Francisco-based 23andMe filed for Chapter 11 bankruptcy protection in the Eastern Missouri federal court district in ...
Don't Blame 23andMe for the Federal Government's Lack of Clear Data Privacy Rules
A lawsuit against genomics firm 23andMe is stirring a debate about what the proper role of government is in regulating how private companies use sensitive data. In June, 27 states filed a lawsuit ...